NasdaqGM - Nasdaq Real Time Price • USD
Chimerix, Inc. (CMRX)
As of 10:49 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -0.22 | -0.23 | -0.85 | -0.96 |
| Low Estimate | -0.26 | -0.27 | -1.05 | -1.15 |
| High Estimate | -0.17 | -0.17 | -0.7 | -0.7 |
| Year Ago EPS | -0.24 | -0.21 | -0.93 | -0.85 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 6 | 7 |
| Avg. Estimate | 50k | 50k | 5.17M | 2.14M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 250k | 250k | 30M | 9M |
| Year Ago Sales | 283k | 230k | 324k | 5.17M |
| Sales Growth (year/est) | -82.30% | -78.30% | 1,495.70% | -58.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.25 | -0.24 | -0.23 | -0.24 |
| EPS Actual | -0.24 | -0.21 | -0.27 | -0.2 |
| Difference | 0.01 | 0.03 | -0.04 | 0.04 |
| Surprise % | 4.00% | 12.50% | -17.40% | 16.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.22 | -0.23 | -0.85 | -0.96 |
| 7 Days Ago | -0.22 | -0.23 | -0.85 | -0.96 |
| 30 Days Ago | -0.22 | -0.23 | -0.85 | -0.96 |
| 60 Days Ago | -0.22 | -0.22 | -0.82 | -0.94 |
| 90 Days Ago | -0.22 | -0.22 | -0.82 | -0.94 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CMRX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 8.30% | -- | -- | 0.80% |
| Next Qtr. | -9.50% | -- | -- | 9.60% |
| Current Year | 8.60% | -- | -- | 4.50% |
| Next Year | -12.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/1/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 8/17/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/16/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/4/2023 |
| Initiated | Baird: Outperform | 5/23/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 5/5/2023 |
Related Tickers
GOSS Gossamer Bio, Inc.
0.8080
+0.25%
ABOS Acumen Pharmaceuticals, Inc.
3.2050
+1.42%
NXTC NextCure, Inc.
1.6100
+2.55%
AVRO AVROBIO, Inc.
1.2214
-1.49%
KZR Kezar Life Sciences, Inc.
0.7966
+1.14%
SPRB Spruce Biosciences, Inc.
0.6998
-0.17%
ACHL Achilles Therapeutics plc
0.8110
+1.34%
CTMX CytomX Therapeutics, Inc.
1.7200
-0.58%
KZIA Kazia Therapeutics Limited
0.3700
+7.25%
ACET Adicet Bio, Inc.
1.9201
-5.18%